Teriparatide attenuates scarring around murine cranial bone allograft via modulation of angiogenesis

Doron Cohn Yakubovich, Uzi Eliav, Eran Yalon, Yeshai Schary, Dmitriy Sheyn, Galen Cook-Wiens, Shuting Sun, Charles E. McKenna, Shaya Lev, Alexander M. Binshtok, Gadi Pelled, Gil Navon, Dan Gazit, Zulma Gazit*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Nearly all bone fractures in humans can deteriorate into a non-union fracture, often due to formation of fibrotic tissue. Cranial allogeneic bone grafts present a striking example: although seemingly attractive for craniofacial reconstructions, they often fail due to fibrosis at the host-graft junction, which physically prevents the desired bridging of bone between the host and graft and revitalization of the latter. In the present study we show that intermittent treatment with recombinant parathyroid hormone-analogue (teriparatide) modulates neovascularization feeding in the graft surroundings, consequently reducing fibrosis and scar tissue formation and facilitates osteogenesis. Longitudinal inspection of the vascular tree feeding the allograft has revealed that teriparatide induces formation of small-diameter vessels in the 1st week after surgery; by the 2nd week, abundant formation of small-diameter blood vessels was detected in untreated control animals, but far less in teriparatide-treated mice, although in total, more blood capillaries were detected in the animals that were given teriparatide. By that time point we observed expression of the profibrogenic mediator TGF-β in untreated animals, but negligible expression in the teriparatide-treated mice. To evaluate the formation of scar tissue, we utilized a magnetization transfer contrast MRI protocol to differentiate osteoid tissue from scar tissue, based on the characterization of collagen fibers. Using this method we found that significantly more bone matrix was formed in animals given teriparatide than in control animals. Altogether, our findings show how teriparatide diminishes scarring, ultimately leading to superior bone graft integration.

Original languageAmerican English
Pages (from-to)192-200
Number of pages9
StatePublished - 1 Apr 2017

Bibliographical note

Publisher Copyright:
© 2017


  • Bioengineering
  • Bone anabolics
  • Bone injury
  • Fracture healing
  • Magnetic resonance imaging
  • Parathyroid hormone


Dive into the research topics of 'Teriparatide attenuates scarring around murine cranial bone allograft via modulation of angiogenesis'. Together they form a unique fingerprint.

Cite this